Trevena (TRVN) Competitors $0.94 -0.16 (-14.55%) As of 07/3/2025 12:34 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock TRVN vs. TTNP, PLRZ, EVOK, LIPO, DRMA, VIVS, CMND, CANF, ARTL, and CEROShould you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Titan Pharmaceuticals (TTNP), Polyrizon (PLRZ), Evoke Pharma (EVOK), Lipella Pharmaceuticals (LIPO), Dermata Therapeutics (DRMA), VivoSim Labs (VIVS), Clearmind Medicine (CMND), Can-Fite BioPharma (CANF), Artelo Biosciences (ARTL), and CERo Therapeutics (CERO). These companies are all part of the "pharmaceutical products" industry. Trevena vs. Its Competitors Titan Pharmaceuticals Polyrizon Evoke Pharma Lipella Pharmaceuticals Dermata Therapeutics VivoSim Labs Clearmind Medicine Can-Fite BioPharma Artelo Biosciences CERo Therapeutics Trevena (NASDAQ:TRVN) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability. Do analysts prefer TRVN or TTNP? Trevena currently has a consensus price target of $5.00, suggesting a potential upside of 431.91%. Given Trevena's stronger consensus rating and higher possible upside, equities analysts plainly believe Trevena is more favorable than Titan Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Titan Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals hold more shares of TRVN or TTNP? 13.6% of Trevena shares are owned by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 0.7% of Titan Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, TRVN or TTNP? Trevena has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Which has preferable earnings and valuation, TRVN or TTNP? Titan Pharmaceuticals has lower revenue, but higher earnings than Trevena. Titan Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevena$443K2.03-$40.29M-$47.04-0.02Titan Pharmaceuticals$180K22.24-$4.71M-$4.59-0.96 Does the media refer more to TRVN or TTNP? In the previous week, Titan Pharmaceuticals had 2 more articles in the media than Trevena. MarketBeat recorded 3 mentions for Titan Pharmaceuticals and 1 mentions for Trevena. Titan Pharmaceuticals' average media sentiment score of 0.18 beat Trevena's score of 0.00 indicating that Titan Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevena 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Titan Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TRVN or TTNP more profitable? Trevena's return on equity of 0.00% beat Titan Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets TrevenaN/A N/A -119.55% Titan Pharmaceuticals N/A -145.92%-129.20% SummaryTrevena and Titan Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get Trevena News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVN vs. The Competition Export to ExcelMetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$901K$839.47M$5.55B$9.05BDividend YieldN/A4.84%5.24%4.01%P/E Ratio-0.021.1527.6120.23Price / Sales2.03228.55417.23118.52Price / CashN/A23.4436.8958.10Price / Book-0.086.328.035.67Net Income-$40.29M-$27.99M$3.18B$249.21M7 Day Performance-15.32%2.11%2.93%3.28%1 Month Performance-10.65%10.13%3.75%5.55%1 Year Performance-82.91%11.60%35.20%21.09% Trevena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVNTrevena1.6276 of 5 stars$0.94-14.5%$5.00+431.9%-81.9%$901K$443K-0.0240Gap DownTTNPTitan Pharmaceuticals0.3004 of 5 stars$4.20-4.5%N/A-17.1%$4.02M$180K-0.9210PLRZPolyrizonN/A$0.740.0%N/AN/A$3.94MN/A0.00N/ANews CoveragePositive NewsGap DownEVOKEvoke PharmaN/A$2.60-1.1%N/A-57.9%$3.92M$10.25M-0.914LIPOLipella Pharmaceuticals1.3413 of 5 stars$0.87-3.6%N/A-77.9%$3.88M$536.36K-0.214DRMADermata Therapeutics1.4982 of 5 stars$0.59-3.2%$3.00+412.8%-70.1%$3.85MN/A-0.048VIVSVivoSim LabsN/A$1.47flatN/AN/A$3.82M$140K-0.1420Gap UpCMNDClearmind Medicine0.6084 of 5 stars$0.90+1.2%N/A-26.8%$3.79MN/A-0.82N/AGap DownCANFCan-Fite BioPharma3.3013 of 5 stars$1.05+1.0%$14.00+1,233.3%-57.9%$3.72M$674K-0.598ARTLArtelo Biosciences2.9798 of 5 stars$13.27+95.4%$33.00+148.7%+32.3%$3.71MN/A-0.745High Trading VolumeCEROCERo Therapeutics3.2788 of 5 stars$9.63+0.8%$45.00+367.3%-98.2%$3.69MN/A0.008Gap Up Related Companies and Tools Related Companies TTNP Alternatives PLRZ Alternatives EVOK Alternatives LIPO Alternatives DRMA Alternatives VIVS Alternatives CMND Alternatives CANF Alternatives ARTL Alternatives CERO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
